Latest News about BIIB
Recent news which mentions BIIB
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
Tags
Stocks to Buy
PYXS
NASDAQ:VRTX,NASDAQ:AMGN,NASDAQ:GILD,NASDAQ:BIIB,NASDAQ:PYXS,NASDAQ:VKTX,NASDAQ:ALT
From InvestorPlace
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024
February 19, 2024
From InvestorPlace
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
Tags
NYSE:TMO,NASDAQ:AMGN,NYSE:NVS,NASDAQ:GILD,NYSE:BMY,NASDAQ:AZN,NASDAQ:SNY,NASDAQ:BIIB
Stocks to Buy
SNY
From InvestorPlace
From Benzinga
From Benzinga
Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday?
February 13, 2024
From Benzinga
Why Is Biogen Stock Trading Lower On Tuesday?
February 13, 2024
From Benzinga
Nasdaq, S&P 500 Set For Weaker Open As Traders Keep Eyes Peeled On Inflation Data: Analyst Flags Key CPI Report Item To Watch
February 13, 2024
From Benzinga
Earnings Scheduled For February 13, 2024
February 13, 2024
From Benzinga
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
February 12, 2024
From InvestorPlace
From Benzinga
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
From InvestorPlace
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
January 31, 2024
From Benzinga
NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
January 29, 2024
From Benzinga
From Benzinga
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
January 24, 2024
From Benzinga
Critical Insights From Biogen Analyst Ratings: What You Need To Know
January 24, 2024
Tickers
BIIB
From Benzinga
Highlights From the 2024 JPMorgan Health Care Conference
January 22, 2024
From Motley Fool
From Motley Fool
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
January 12, 2024
From Benzinga
From Benzinga
Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments
January 10, 2024
From Benzinga
Comparing Biogen With Industry Competitors In Biotechnology Industry
January 10, 2024
From Benzinga
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
January 03, 2024
From Motley Fool
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
January 02, 2024
From InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.